Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04546724 · ClinicalTrials.gov registry record · Phase 3
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
A Phase 3 study, sponsored by Valneva Austria.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,128
- Enrollment target
NCT04546724 is a Phase 3 study that has completed, run by Valneva Austria. The registered enrollment target is 4,128 participants.
The verdict
NCT04546724, a Phase 3 study, has completed, sponsored by Valneva Austria.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,128 participants
- Enrollment target
Study Summary
This was a prospective, randomized, double-blinded, multicenter, pivotal clinical study evaluating the final dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The final dose of VLA1553 or control was administered as single immunization on Day 1. Overall, 4.128 male and female subjects aged 18 years and above were randomized into the study.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VLA1553
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,128 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2021-10-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04546724
The ClinicalTrials.gov registry entry for NCT04546724 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Valneva Austria, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04546724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04546724 about?
NCT04546724 is a clinical study titled "Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults". This was a prospective, randomized, double-blinded, multicenter, pivotal clinical study evaluating the final dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The final dose of VLA1553 or control was administered as single immunization on Day 1. Overall, 4.128 male and fe...
What is the current status of trial NCT04546724?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,128 participants. The study started on 2020-09-17. Estimated completion is 2021-10-15.
What interventions are being tested in trial NCT04546724?
The interventions under investigation include: Placebo (BIOLOGICAL), VLA1553 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04546724?
This trial is sponsored by Valneva Austria, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.